0001140361-25-027350.txt : 20250725 0001140361-25-027350.hdr.sgml : 20250725 20250725164319 ACCESSION NUMBER: 0001140361-25-027350 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250721 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250725 DATE AS OF CHANGE: 20250725 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 251152140 BUSINESS ADDRESS: STREET 1: ROUTE 206 AND PROVINCE LINE ROAD CITY: PRINCETON STATE: NJ ZIP: 08543 BUSINESS PHONE: 6092524621 MAIL ADDRESS: STREET 1: ROUTE 206 AND PROVINCE LINE ROAD CITY: PRINCETON STATE: NJ ZIP: 08543 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 ef20052589_8k.htm CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 21, 2025

BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)

Delaware
001-01136
22-0790350
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S Employer Identification No.)
Route 206 & Province Line Road, Princeton, New Jersey 08543
(Address of principal executive offices) (Zip Code)

(Registrant’s telephone number, including area code): (609) 252-4621

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 Par Value
BMY
New York Stock Exchange
1.750% Notes due 2035
BMY35
New York Stock Exchange
Celgene Contingent Value Rights
CELG RT
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) On July 25, 2025, Bristol-Myers Squibb Company (the “Company”) announced that Dr. Samit Hirawat, Chief Medical Officer and Head of Development, will leave the Company by November 1, 2025. In connection with his departure, Dr. Hirawat will transition from his current role as Executive Vice President, Chief Medical Officer and Head of Development, effective August 1, 2025, to become an advisor to the Company.

(e)  In connection with his departure, Dr. Hirawat will be entitled to (i) severance benefits in accordance with the Company’s U.S. Severance Benefits Plan, (ii) pro-rated vesting of Market Share Units (MSUs) and Performance Share Units (PSUs), in each case, in accordance with the Company’s equity award agreements under the Company’s 2021 Stock Award and Incentive Plan, and (iii) a prorated annual incentive payout for 2025 in accordance with the Company’s Senior Executive Performance Incentive Plan.

A copy of the press release announcing the departure of Dr. Hirawat is attached to this report as Exhibit 99.1.

Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:

Exhibit
No.
  
Description
     
 
Press release of Bristol-Myers Squibb Company dated July 25, 2025.
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
Dated: July 25, 2025
By:
/s/ Amy Fallone
 
Name:
Amy Fallone
 
Title:
Corporate Secretary


EX-99.1 2 ef20052589_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1
 
 
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
 
Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team

Samit Hirawat, M.D., Executive Vice President, to step down from his role on August 1 and will depart BMS on November 1

PRINCETON, N.J., [BUSINESS WIRE] – Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company’s early-stage and late-stage product development across all therapeutic areas.
 
“We are thrilled to welcome Cristian to Bristol Myers Squibb,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. “His deep scientific expertise, strong focus on clinical execution and proven track record of regulatory approvals will be instrumental as we continue to advance our pipeline and deliver breakthrough medicines to even more patients around the world. Cristian also has a very strong track record of building and developing world-class teams.”
 
“I am on a mission to discover new medicines - unlocking innovative approaches to researching and treating challenging diseases so that one day, no patient will hear that all options have been exhausted. I am excited to join BMS in this shared purpose, with its storied history, vast pipeline across therapeutic areas, exceptional reputation, and culture deeply committed to making a difference,” said Dr. Massacesi.
 
Samit Hirawat, M.D., Bristol Myers Squibb’s Executive Vice President, Chief Medical Officer, and Head of Development for the past six years, is stepping down to pursue new professional opportunities. Dr. Hirawat will transition from his current role, effective August 1, 2025, and will remain an advisor to the Company through November 1, 2025, to ensure a seamless transition.
 
Boerner continued, "We sincerely thank Samit for his leadership and dedication to innovative drug development at BMS over the past six years. Under his guidance, we have advanced groundbreaking science that has culminated in the approval of many new products across oncology, hematology, immunology, cardiovascular, and neuroscience. His commitment and visionary approach have driven our progress and positioned us at the forefront of impactful medical innovation."
 
About Cristian Massacesi, M.D.
 
Dr. Massacesi began his career in the healthcare field as a medical oncologist, bringing the ethos of putting patients first into his more than 20 years of global biopharmaceutical experience. He has a proven track record of advancing breakthrough science from early through late-stage development and global regulatory approvals, inspiring and encouraging his teams to identify novel strategies and take smart risks.
 
He most recently served as Chief Medical Officer of AstraZeneca and Alexion and as Oncology Chief Development Officer at AstraZeneca, where he led a global organization of more than 3,000 employees. Under his leadership, AstraZeneca advanced over 150 clinical studies and secured multiple regulatory approvals. Prior to his tenure at AstraZeneca, Dr. Massacesi held senior R&D positions at Pfizer and Novartis, where he oversaw development programs across solid tumors and hematologic malignancies.
 
Dr. Massacesi will be based in Princeton, New Jersey, and report directly to Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb.
 
About Bristol Myers Squibb: Transforming Patients' Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

###
 
corporatefinancial-news
 
Media Inquiries:
media@bms.com
 
Investors:
investor.relations@bms.com
 

 EX-101.SCH 3 bmy-20250721.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bmy-20250721_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bmy-20250721_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Common Stock [Member] Class of Stock [Domain] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Celgene Contingent Value Rights [Member] 1.750% Notes due 2035 [Member] EX-101.PRE 6 bmy-20250721_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image00001.jpg begin 644 image00001.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.25.2
Document and Entity Information
Jul. 21, 2025
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 21, 2025
Entity File Number 001-01136
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Central Index Key 0000014272
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One Route 206 & Province Line Road
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08543
City Area Code 609
Local Phone Number 252-4621
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY35
Security Exchange Name NYSE
Celgene Contingent Value Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Celgene Contingent Value Rights
Trading Symbol CELG RT
Security Exchange Name NYSE
XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.2 html 4 22 1 false 3 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bms.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports bmy-20250721.xsd bmy-20250721_def.xml bmy-20250721_lab.xml bmy-20250721_pre.xml ef20052589_8k.htm http://xbrl.sec.gov/dei/2025 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20052589_8k.htm": { "nsprefix": "bmy", "nsuri": "http://bms.com/20250721", "dts": { "schema": { "local": [ "bmy-20250721.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/exch/2025/exch-2025.xsd", "https://xbrl.sec.gov/naics/2025/naics-2025.xsd", "https://xbrl.sec.gov/sic/2025/sic-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "definitionLink": { "local": [ "bmy-20250721_def.xml" ] }, "labelLink": { "local": [ "bmy-20250721_lab.xml" ] }, "presentationLink": { "local": [ "bmy-20250721_pre.xml" ] }, "inline": { "local": [ "ef20052589_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 4, "entityCount": 1, "segmentCount": 3, "elementCount": 36, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 28 }, "report": { "R1": { "role": "http://bms.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20250721to20250721", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20052589_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20250721to20250721", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20052589_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "bmy_CelgeneContingentValueRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://bms.com/20250721", "localname": "CelgeneContingentValueRightsMember", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Celgene Contingent Value Rights [Member]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockMember", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingsLineItems", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingsTable", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "bmy_One750NotesDue2035Member": { "xbrltype": "domainItemType", "nsuri": "http://bms.com/20250721", "localname": "One750NotesDue2035Member", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "1.750% Notes due 2035 [Member]" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001140361-25-027350-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-25-027350-xbrl.zip M4$L#!!0 ( &B%^5HGCEG4SP, *T1 0 8FUY+3(P,C4P-S(Q+GAS M9,U7VV[C-A!]+]!_8/6NFQTWC1%GT6YV%P&RFR+=%GU;T-+8(4J1*DEM[+_O MD!)E^5K+:M&^D9QSYL;1:'C[9E5P\A649E+,@C1* @(BDSD3RUE0Z9#JC+'@ MS=VWW]Q^%X8?0("B!G(R7Y.?E*2Y8OD2R,_/3PO&@8PFT7641I/QZ*HC#D-+ M7^FISEZ@H,10M03SB1:@2YK!+'@QIIS&\;S042:+>)2,)LGU*$57.!0@S'NI MBGM8T(J;6?!G13E;,,@#@KX+/5WI5L/KZVOT.HZD6J*2)(U___CXB[/IL?-B M?<)%,_+&E<357W.L&8S.O6W M\ P+XG(\M0IG@69%R6T"W=F+@L4LP$L/_25_*15$Z*!'*,GAQ(U8<8P4C57H M''O'O7;B'+F7664[UX\B?R<,,^L'+&%5N!(*",MGP4E$:]-; MW5S678*-+4E(2+R&[I**G-3J2$??;;RK9%=_I2%_$G=NO5ON#;N!G&)FE&<5 MOX"X78N'>+ 58S60FCUGTL=RE^,\2# M2BF- BW>K 88%99GN8WE#J)<#;&N6];'LX7;1S^IN MV[ZINZ6 I1TJ#YO?I7&EMEBAU1.FHS#]?K@?IKJ5?H]WJV$7 MT)TYSPG<4>PN]#P;_MB&/TXO]N(J5O9??:8##FW-XGSZ0Y@F_;*^-S^?:=43 MK.'S\WUL1![P=W%JAGYVS4"$_F4FA%7)J:!&JO5[W)__"72UO-LHN>2+Z+X- M>N7(X^O\V)=%K]0<>Y-<;'WH]1Q\@!USYN^8;J]W'6E>U2#DE4Y"]R[>,H0$A#!.$[Q=E8WJD(X1;3"^O+[&HMS.I/YY]I4I9JY M^EB(3P*N)\DG:4#?5S!*QI/=P(XC_N-PW#A;7__=7U!+ P04 " !HA?E: MX'C.A1 ' !E1@ % &)M>2TR,#(U,#&ULU9Q=4^,V%(;O M.]/_D*;7B4FR*879[ X-T,F4!0;HYPVCV$JB65MB)&4)_[Z2(X%E2[;R@=>Y M@<1Z?71>/9(MRW8^?EXE<>L;I P1/&KWND?M%L0AB1">C]I+U@$L1*C]^=./ M/WS\J=/Y'6)( 8=1:_K2^HT2$%$4S6'K]NYFAF+8Z@^[Q]U>=SCH?\@4=SIR M]QCAKZ?RSQ0PV!+58G:Z8FC47G#^=!H$S\_/W>=!E]!YT#\ZZ@7_?+FZ#Q

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end XML 17 ef20052589_8k_htm.xml IDEA: XBRL DOCUMENT 0000014272 2025-07-21 2025-07-21 0000014272 bmy:CelgeneContingentValueRightsMember 2025-07-21 2025-07-21 0000014272 bmy:One750NotesDue2035Member 2025-07-21 2025-07-21 0000014272 us-gaap:CommonStockMember 2025-07-21 2025-07-21 false 0000014272 8-K 2025-07-21 BRISTOL-MYERS SQUIBB COMPANY DE 001-01136 22-0790350 Route 206 & Province Line Road Princeton NJ 08543 609 252-4621 false false false false Common Stock, $0.10 Par Value BMY NYSE 1.750% Notes due 2035 BMY35 NYSE Celgene Contingent Value Rights CELG RT NYSE false